By Jonathan Pearson-Stuttard and James O’Shaughnessy2022-12-14T12:42:00
Realignment of R&D investment could generate a better return on R&D investment to UK plc by improving access to innovative medicines, reducing variations in health outcomes, reengaging people with the labour market, and improving healthy life expectancy, write Jonathan Pearson-Stuttard and James O’Shaughnessy.
Certain articles and Insight pieces remain paying-subscriber only content
As a registered user you will get access to:
Already registered to HSJ? Sign in now
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud